CN103360411A - 依维莫司结晶提纯方法 - Google Patents
依维莫司结晶提纯方法 Download PDFInfo
- Publication number
- CN103360411A CN103360411A CN2013103007949A CN201310300794A CN103360411A CN 103360411 A CN103360411 A CN 103360411A CN 2013103007949 A CN2013103007949 A CN 2013103007949A CN 201310300794 A CN201310300794 A CN 201310300794A CN 103360411 A CN103360411 A CN 103360411A
- Authority
- CN
- China
- Prior art keywords
- everolimus
- crystallization
- water
- crude product
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 title claims abstract description 164
- 229960005167 everolimus Drugs 0.000 title claims abstract description 163
- 238000000746 purification Methods 0.000 title claims abstract description 49
- 238000002425 crystallisation Methods 0.000 title claims abstract description 48
- 230000008025 crystallization Effects 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000012043 crude product Substances 0.000 claims abstract description 44
- 239000013078 crystal Substances 0.000 claims abstract description 36
- 239000003960 organic solvent Substances 0.000 claims abstract description 25
- 239000000047 product Substances 0.000 claims abstract description 22
- 150000001335 aliphatic alkanes Chemical class 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 238000003756 stirring Methods 0.000 claims abstract description 15
- 238000004440 column chromatography Methods 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 45
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000741 silica gel Substances 0.000 claims description 24
- 229910002027 silica gel Inorganic materials 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000010606 normalization Methods 0.000 claims description 12
- 229960000583 acetic acid Drugs 0.000 claims description 10
- 239000012362 glacial acetic acid Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 7
- 150000001298 alcohols Chemical class 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 230000000630 rising effect Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 8
- 239000012535 impurity Substances 0.000 abstract description 8
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- RIRARCHMRDHZAR-UHFFFAOYSA-N CC1C(C)CCC1 Chemical compound CC1C(C)CCC1 RIRARCHMRDHZAR-UHFFFAOYSA-N 0.000 description 1
- 0 COC1=C*N=C[C@](CCCCCCC2)[C@]12[N+]([O-])=O Chemical compound COC1=C*N=C[C@](CCCCCCC2)[C@]12[N+]([O-])=O 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 229940042992 afinitor Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310300794.9A CN103360411B (zh) | 2013-07-17 | 2013-07-17 | 依维莫司结晶提纯方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310300794.9A CN103360411B (zh) | 2013-07-17 | 2013-07-17 | 依维莫司结晶提纯方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103360411A true CN103360411A (zh) | 2013-10-23 |
CN103360411B CN103360411B (zh) | 2015-09-30 |
Family
ID=49362756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310300794.9A Active CN103360411B (zh) | 2013-07-17 | 2013-07-17 | 依维莫司结晶提纯方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103360411B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104892632A (zh) * | 2015-06-03 | 2015-09-09 | 道中道(菏泽)制药有限公司 | 一种晶体形式的依维莫司及其制备方法 |
CN105566348A (zh) * | 2015-12-31 | 2016-05-11 | 哈药集团技术中心 | 一种依维莫司的制备方法 |
CN106146535A (zh) * | 2015-04-25 | 2016-11-23 | 山东新时代药业有限公司 | 一种依维莫司的制备方法 |
CN108676014A (zh) * | 2018-06-15 | 2018-10-19 | 国药集团川抗制药有限公司 | 纯化依维莫司中间体的方法以及制备依维莫司的方法 |
CN116813642A (zh) * | 2023-06-29 | 2023-09-29 | 杭州华东医药集团康润制药有限公司 | 一种依维莫司纯化方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665772A (en) * | 1992-10-09 | 1997-09-09 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
CN1768066A (zh) * | 2003-03-31 | 2006-05-03 | 特瓦药厂有限公司 | 大环内酯物质的结晶与纯化 |
CN1856500A (zh) * | 2003-07-24 | 2006-11-01 | 特瓦药厂私人有限公司 | 纯化大环内酯类化合物的方法 |
US20070078258A1 (en) * | 1995-03-29 | 2007-04-05 | Peter Fuenfschilling | Purification process |
CN101137659A (zh) * | 2005-03-07 | 2008-03-05 | 惠氏公司 | 42-o-(2-羟基)乙基-雷帕霉素的氧杂环庚烷异构体 |
CN102127092A (zh) * | 2010-01-18 | 2011-07-20 | 东南大学 | 依维莫斯的制备 |
CN102174053A (zh) * | 2011-03-09 | 2011-09-07 | 成都雅途生物技术有限公司 | 依维莫司的纯化方法 |
WO2012066502A1 (en) * | 2010-11-19 | 2012-05-24 | Biocon Limited | Processes for preparation of everolimus and intermediates thereof |
WO2012103959A1 (en) * | 2011-02-04 | 2012-08-09 | Synthon Bv | Process for making everolimus |
-
2013
- 2013-07-17 CN CN201310300794.9A patent/CN103360411B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665772A (en) * | 1992-10-09 | 1997-09-09 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
US20070078258A1 (en) * | 1995-03-29 | 2007-04-05 | Peter Fuenfschilling | Purification process |
CN1768066A (zh) * | 2003-03-31 | 2006-05-03 | 特瓦药厂有限公司 | 大环内酯物质的结晶与纯化 |
CN1856500A (zh) * | 2003-07-24 | 2006-11-01 | 特瓦药厂私人有限公司 | 纯化大环内酯类化合物的方法 |
CN101137659A (zh) * | 2005-03-07 | 2008-03-05 | 惠氏公司 | 42-o-(2-羟基)乙基-雷帕霉素的氧杂环庚烷异构体 |
CN102127092A (zh) * | 2010-01-18 | 2011-07-20 | 东南大学 | 依维莫斯的制备 |
WO2012066502A1 (en) * | 2010-11-19 | 2012-05-24 | Biocon Limited | Processes for preparation of everolimus and intermediates thereof |
WO2012103959A1 (en) * | 2011-02-04 | 2012-08-09 | Synthon Bv | Process for making everolimus |
CN102174053A (zh) * | 2011-03-09 | 2011-09-07 | 成都雅途生物技术有限公司 | 依维莫司的纯化方法 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106146535A (zh) * | 2015-04-25 | 2016-11-23 | 山东新时代药业有限公司 | 一种依维莫司的制备方法 |
CN106146535B (zh) * | 2015-04-25 | 2019-07-26 | 山东新时代药业有限公司 | 一种依维莫司的制备方法 |
CN104892632A (zh) * | 2015-06-03 | 2015-09-09 | 道中道(菏泽)制药有限公司 | 一种晶体形式的依维莫司及其制备方法 |
CN104892632B (zh) * | 2015-06-03 | 2017-12-26 | 道中道(菏泽)制药有限公司 | 一种晶体形式的依维莫司及其制备方法 |
CN105566348A (zh) * | 2015-12-31 | 2016-05-11 | 哈药集团技术中心 | 一种依维莫司的制备方法 |
CN108676014A (zh) * | 2018-06-15 | 2018-10-19 | 国药集团川抗制药有限公司 | 纯化依维莫司中间体的方法以及制备依维莫司的方法 |
CN116813642A (zh) * | 2023-06-29 | 2023-09-29 | 杭州华东医药集团康润制药有限公司 | 一种依维莫司纯化方法 |
CN116813642B (zh) * | 2023-06-29 | 2024-04-19 | 浙江康润制药有限公司 | 一种依维莫司纯化方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103360411B (zh) | 2015-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103360411B (zh) | 依维莫司结晶提纯方法 | |
CN104402838B (zh) | 缬沙坦的精制方法 | |
CN102050737A (zh) | 一种截短侧耳素的提取纯化方法 | |
CN102584692B (zh) | 盐酸吡哆醇的制备方法 | |
CN103896930B (zh) | 卡格列净半水合物药用晶型的制备方法 | |
CN102020625A (zh) | 一种高纯度的鲁比前列酮及其制备方法和用途 | |
CN102533431A (zh) | 从沙棘果肉中连续提取分离沙棘油和异鼠李素的方法 | |
CN103242251B (zh) | 一种来曲唑的制备方法 | |
CN102993135B (zh) | 一种奥利司他的纯化方法 | |
CN1289609C (zh) | 一种番茄红素结晶及其浓缩物的制备方法 | |
CN102432516B (zh) | 奥拉西坦的精制方法 | |
CN102746283B (zh) | 高纯度水飞蓟宾的制备方法 | |
CN109020933B (zh) | 一种麦考酚酸的纯化方法 | |
CN102432575A (zh) | 一种从枳实中提取高纯度橙皮素的方法 | |
CN104744389A (zh) | 从缬沙坦结晶母液中回收缬沙坦甲酯的方法 | |
CN105949184B (zh) | 一种盐酸阿罗洛尔的精制方法 | |
CN101514163B (zh) | 光学纯西布曲明及其衍生盐的制备工艺 | |
CN110627806A (zh) | 一种银杏内酯b化合物及其制备方法 | |
CN1974564B (zh) | 一种霉酚酸莫啡酯的制备方法 | |
CN110862429A (zh) | 一种七叶皂苷钠的制备方法 | |
CN116768910B (zh) | 一种利福布汀的精制方法 | |
CN106905394A (zh) | 一种高效回收利用曲克芦丁结晶母液的方法 | |
CN106336401A (zh) | 一种阿伐那非的精制方法 | |
CN101570564B (zh) | 一种丹参酮ⅱa丙烯酸的精制方法 | |
CN104098510B (zh) | 一种从高乌头植物根中提取高乌甲素的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Everolimus crystallization purification method Effective date of registration: 20180413 Granted publication date: 20150930 Pledgee: Chengdu technical transformation incubator management Co., Ltd. Pledgor: Chengdu Yatu Biotechnology Co., Ltd. Registration number: 2018510000042 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190417 Granted publication date: 20150930 Pledgee: Chengdu technical transformation incubator management Co., Ltd. Pledgor: Chengdu Yatu Biotechnology Co., Ltd. Registration number: 2018510000042 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Everolimus crystallization purification method Effective date of registration: 20190425 Granted publication date: 20150930 Pledgee: Chengdu technical transformation incubator management Co., Ltd. Pledgor: Chengdu Yatu Biotechnology Co., Ltd. Registration number: 2019510000049 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200708 Granted publication date: 20150930 Pledgee: Chengdu technical transformation incubator management Co.,Ltd. Pledgor: YACHT BIOTECHNOLOGY Co. Registration number: 2019510000049 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |